Infinity Pharmaceuticals Inc expected to post a loss of 13  cents a share - Earnings Preview

Infinity Pharmaceuticals

30/04/2022 03:06

* Infinity Pharmaceuticals Inc  INFI.OQ   INFI.O  is
expected
to show a fall in quarterly revenue when it reports  results on
May 3. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 26.1% decrease in revenue to $345.17 thousand from $467
thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Infinity
Pharmaceuticals
Inc is for a loss of 13 cents per share. For the same quarter
last year, the company reported a loss of 15 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Infinity
Pharmaceuticals Inc is $5​, above​ its last closing price
of $0.79. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.14       -0.13      -0.13     Met     3.7
 Sep. 30 2021  -0.13       -0.13      -0.12     Beat    10.8
 Jun. 30 2021  -0.14       -0.14      -0.13     Beat    4.4​
 Mar. 31 2021  -0.12       -0.12      -0.15     Missed  -20.2
 ​​Dec.        -0.16       -0.16      -0.16     Met     -2.1
 31 2020                                                
 Sep. 30 2020  -0.15       -0.16      -0.16     Met     -2.6​
 Jun. 30 2020  -0.20       -0.19      -0.16     Beat    16.1
 Mar. 31 2020  -0.12       -0.13      -0.19     Missed  -43.7
 This summary was machine generated April 30 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated